OPKO Health (NASDAQ:OPK) Downgraded by Wall Street Zen to Sell

OPKO Health (NASDAQ:OPK) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other brokerages also recently commented on OPK. JPMorgan Chase & Co. assumed coverage on OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating on the stock. Barrington Research dropped their price target on OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $2.03.

OPKO Health Trading Up 0.9%

Shares of OPK stock opened at $1.18 on Friday. OPKO Health has a 12-month low of $1.11 and a 12-month high of $1.95. The company has a market capitalization of $895.70 million, a P/E ratio of -3.93 and a beta of 1.50. The firm has a 50-day moving average price of $1.26 and a 200 day moving average price of $1.35. The company has a quick ratio of 3.32, a current ratio of 3.97 and a debt-to-equity ratio of 0.26.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. The firm had revenue of $148.50 million for the quarter, compared to analysts’ expectations of $139.76 million. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. The company’s quarterly revenue was down 19.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.01 earnings per share. Research analysts forecast that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OPKO Health

Several large investors have recently made changes to their positions in OPK. Comerica Bank boosted its holdings in OPKO Health by 7.1% in the fourth quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock valued at $151,000 after acquiring an additional 8,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in OPKO Health by 4.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock valued at $262,000 after purchasing an additional 8,954 shares during the period. The Manufacturers Life Insurance Company lifted its position in OPKO Health by 11.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 13,912 shares during the period. Intech Investment Management LLC boosted its stake in shares of OPKO Health by 11.4% in the 4th quarter. Intech Investment Management LLC now owns 159,652 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 16,329 shares during the last quarter. Finally, Caprock Group LLC acquired a new stake in shares of OPKO Health during the 3rd quarter worth approximately $26,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.